Skip to main content
Clinical Trials/NCT03245437
NCT03245437
Completed
Phase 4

Effects of Oxytocin on Social Cognition Training: Relationship to Target Engagement

University of California, Los Angeles1 site in 1 country120 target enrollmentJanuary 4, 2018

Overview

Phase
Phase 4
Intervention
Oxytocin nasal spray
Conditions
Schizophrenia
Sponsor
University of California, Los Angeles
Enrollment
120
Locations
1
Primary Endpoint
Social Cognition Composite Score
Status
Completed
Last Updated
last year

Overview

Brief Summary

This study will measure whether the engagement of intranasal oxytocin with a brain target is related to effects on learning during a social cognition training program.

Detailed Description

The study will determine whether oxytocin (OT) administration 30 min before a training session enhances the learning of social information in the context of a social cognitive skills training (SCST) program, and it will test a possible mediator of this effect. Subjects with psychotic disorders will be randomized to one of four groups in a 2 by 2 factorial design: OT with SCST; Placebo with SCST; OT with training control condition; placebo with training control condition. Target engagement will be measured in an OT challenge (placebo versus OT one week apart) prior to baseline assessment. The measure of target engagement will be EEG mu suppression while observing biological motion. A social cognition battery will be administered at baseline, at midpoint after 6 weeks of SCST, and at completion of training at 12 weeks. The battery will include measures of social cue identification and mentalizing.

Registry
clinicaltrials.gov
Start Date
January 4, 2018
End Date
July 31, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Stephen R. Marder

Professor

University of California, Los Angeles

Eligibility Criteria

Inclusion Criteria

  • Schizophrenia or schizoaffective disorder
  • stable on an antipsychotic medication

Exclusion Criteria

  • positive pregnancy test history of head injury

Arms & Interventions

Oxytocin with SCST

Oxytocin with SCST (active condition)

Intervention: Oxytocin nasal spray

Oxytocin with SCST

Oxytocin with SCST (active condition)

Intervention: Social Cognition Skills Training

Oxytocin with Health Management

Administration of OT with control psychosocial treatment

Intervention: Oxytocin nasal spray

Oxytocin with Health Management

Administration of OT with control psychosocial treatment

Intervention: Health Management

Placebo with SCST

Administration of Placebo with active psychosocial treatment

Intervention: Social Cognition Skills Training

Placebo with SCST

Administration of Placebo with active psychosocial treatment

Intervention: Placebo nasal spray

Placebo with HM

Administration of Placebo with control psychosocial treatment

Intervention: Health Management

Placebo with HM

Administration of Placebo with control psychosocial treatment

Intervention: Placebo nasal spray

Outcomes

Primary Outcomes

Social Cognition Composite Score

Time Frame: 16 weeks

We will assess social cognition in two subdomains: (1) social cue identification (Managing Emotions component of Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) branch 1, Ekman, Profile of Nonverbal Sensitivity (PONS); and (2) mentalizing (The Awareness of Social Inference Test (TASIT). and Empathic accuracy) (see below). The primary summary measure for each test will be mean-centered and standardized to create a Z-score. These Z-scores will be averaged to create a single composite score for social cognition that will serve as the primary outcome measure.

Secondary Outcomes

  • Composite score of non-social cognition from the MATRICS Consensus Cognitive Battery(16 weeks)

Study Sites (1)

Loading locations...

Similar Trials